Abstract: The present invention relates to mGluR5 antagonists, or compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, enantiomer, isotope, or mixture thereof, or a pharmaceutical composition comprising said TT00, for use in prevention and/or treatment of bone marrow lesions (BML) and/or osteoporosis, cartilage loss, osteosclerosis, osteitis, or BML related to osteoporosis, cartilage loss, osteosclerosis, osteitis, rheumatoid arthritis, osteosarcoma and/or osteoarthritis or combined with a) pain, b) GERD, c) anxiety and/or d) stress in mammals, such as humans, apes or dogs, cats, pigs, cows or horses.

Abstract: The present invention relates to 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, diastereomer, enantiomer, isotope, pro-drug or metabolite or mixture thereof, or a pharmaceutical composition comprising said TT00, for use in prevention and/or treatment of pain, such as chronic and/or peripheral pain and/or pain related to arthritis, such as osteoarthritis, or for use in prevention and/or treatment of said pain combined with b) GERD or c) anxiety in animals, such as dogs, cats or horses.

Abstract: The present invention relates to compounds 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4 H-1,2,4-triazol-3-yl]pyridine (TT00, TT001 and/or TT002), or a pharmaceutical composition comprising said TT00, TT001 and/or TT002, for use in prevention and/or treatment of surmenage, optionally in combination with one or more disorders selected from operative gastroesophageal reflux, anxiety, ulcer, renal and vascular disorders, wound healing and/or inappetence in a mammal, such as dogs, pigs, cats or horses.

Abstract: The present invention relates to 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, diastereomer, enantiomer, isotope, pro-drug or metabolite or mixture thereof, or a pharmaceutical composition comprising said TT00, for use in prevention and/or treatment of pain, such as chronic and/or peripheral pain and/or pain related to arthritis, such as osteoarthritis, or for use in prevention and/or treatment of said pain combined with b) GERD or c) anxiety in animals, such as dogs, cats or horses.

Abstract: The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the pH of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats.

Abstract: The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the pH of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats.

Abstract: A dispensing device for dosage of powdered material comprises a closed housing containing the powdered material and provided with a laterally displaced outlet for the dosed powdered material. An external manually operated sledge is arranged between the housing and the outlet. The sledge has a through-going pocket for containing the desired dose of the powdered material. When operating the sledge, the through-going pocket is moved from a position in the housing to a position in the outlet so as to effect dispensing of the dose of the powdered material through the action of gravity. The sledge also has an agitator including two posts and a bracket that extends between the posts for agitating the powdered material within the housing. The bracket is slightly arched and the leading edge inclines obliquely downwardly so as to press the powdered material towards the pocket when operating the sledge.

Abstract: A dispensing device for dosage of powdered material comprises a closed housing containing the powdered material and provided with a laterally displaced outlet for the dosed powdered material. An external manually operated sledge is arranged between the housing and the outlet. The sledge has a through-going pocket for containing the desired dose of the powdered material. When operating the sledge, the through-going pocket is moved from a position in the housing to a position in the outlet so as to effect dispensing of the dose of the powdered material through the action of gravity. The sledge also has an agitator comprising two posts and a bracket that extends between the posts for agitating the powdered material within the housing. The bracket is slightly arched and the leading edge inclines obliquely downwardly so as to press the powdered material towards the pocket when operating the sledge.